Journal of Rheumatic Diseases

Table. 2.

Medical and surgical treatments in iRPF patients according to the short-term outcomes of hydronephrosis

Treatment All patients(n=18) With improvement(n=8) Without improvement(n=10) p-value
Medical treatment 10 (56.6) 7 (87.5) 3 (30) 0.025
Glucocorticoid 10 (56.6) 7 (87.5) 3 (30) 0.025
Initial dose (prednisolone, mg/d)* 40 (30∼60) 40 (30∼50) 60 (30∼60) 0.383
Cumulative dose (prednisolone, g)* 2.42 (1.81∼3.69) 2.10 (1.51∼3.30) 3.67 (1.91∼4.27) 0.383
Duration of treatment (mo)* 4.5 (2.3∼6.0) 4.2 (2.1∼5.1) 6.0 (4.5∼6.0) 0.183
Methotrexate 2 (11.1) 2 (25) 0 (0) 0.183
Surgical intervention 12 (66.7) 6 (75) 6 (60) 0.638
Ureteral stenting 11 (61.1) 6 (75) 5 (50) 0.367
Percutaneous nephrostomy 7 (38.9) 3 (37.5) 4 (40) 1.000
Open surgical procedure 1 (5.6) 0 (0) 1 (10) 1.000
Surgical intervention only 4 (22.2) 1 (12.5) 3 (30) 0.588

Data are expressed as number (%) or median (interquartile range). iRPF: idiopathic retroperitoneal fibrosis. *In patients treated with glucocorticoid.

J Rheum Dis 2021;28:38~44 https://doi.org/10.4078/jrd.2021.28.1.38
© J Rheum Dis